Jacques Crémer

Jacques Crémer received his PhD from MIT in 1977 and has held appointments at the University of Pennsylvania and Virginia Tech University. Since 1991 he has been Professor at the Toulouse School of Economics, where he has held many administrative appointments, most recently being the first director of its Digital Centre. He is a Fellow of the Econometric Society and of the European Economic Association. He has done fundamental work on planning theory, auctions, incentive theory, organization economics, and more recently the digital economy. From April 2018 to March 2019, he was a Special Adviser to European Commissioner for Competition Margrethe Vestager, and in that capacity co-authored the report “Competition Policy for the Digital Era”. He is an active participant in the debates on the regulation of “Big Tech”.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More